Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension

NCT01479010 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped recruitment issues, critical investigators left institution

Conditions

Pulmonary Hypertension

Interventions

DRUG: Anakinra 100 mg subcutaneously daily

Sponsor

Virginia Commonwealth University